DWTX, US92829J2033

Dogwood Therapeutics stock posts Q3 loss as Halneuron data nears

Published on 11/19/2026 at 02:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Dogwood Therapeutics stock faces a key Halneuron readout after a completed Phase 2b trial. Funding is set to support operations into early 2027.

Key developments at Dogwood

  • Dogwood completed its 239-patient Phase 2b study of Halneuron for chemotherapy-induced neuropathic pain.
  • A private placement increased available funding and is expected to support operations into the first quarter of 2027.
  • The long-term extension study has enrolled 95 patients, with completion expected in early 2027.
DWTX, US92829J2033, Illustration mit AI erstellt.

Dogwood Therapeutics reported third-quarter results on November 5, 2026, while investors await topline findings from the company’s completed Phase 2b study of Halneuron in chemotherapy-induced neuropathic pain. The company also outlined financing and development milestones in a Dogwood Therapeutics release published by BioSpace.

Quarterly results and trial progress

Revenue reached 100,000 US dollars in the quarter ended September 30, 2026, while research and development expenses fell to 3.3 million US dollars from 14.5 million US dollars a year earlier. General and administrative expenses rose to 1.6 million US dollars from 1.3 million US dollars.

Net loss attributable to common stockholders narrowed to 4.9 million US dollars from 15.7 million US dollars in the year-earlier quarter. Basic and diluted net loss was 0.14 US dollars per share, compared with 8.20 US dollars per share in the prior-year period.

Halneuron remains the central catalyst

Dogwood completed the Phase 2b chemotherapy-induced neuropathic pain study with 239 patients and said topline results were expected in November. The company also fully enrolled 95 patients in a 12-week open-label extension study, which is expected to finish in early 2027.

Dogwood closed a 5 million US dollar private placement with Sealbond Limited, a subsidiary of CK Life Sciences International (Holdings), to support Phase 3 preparations for Halneuron and general corporate purposes. The company said cash on hand of 4.9 million US dollars, together with the placement, should fund operations into the first quarter of 2027.

Business model and competitive field

Dogwood Therapeutics is a US-based development-stage biotechnology company focused on medicines for pain and neuropathy. Its pipeline includes Halneuron, a selective Nav 1.7 sodium channel blocker for chemotherapy-induced neuropathic pain and cancer-related pain, and SP16 IV, an LRP1 agonist being developed for neuropathy and nerve damage. The company is headquartered in Alpharetta, Georgia, and remains focused on clinical development rather than commercial product sales.

Dogwood Therapeutics at a glance

  • Company: Dogwood Therapeutics, Inc.
  • ISIN: US92829J2033
  • Ticker: DWTX
  • Listing: Nasdaq
  • Reporting period: Quarter ended September 30, 2026
  • Lead program: Halneuron Phase 2b for chemotherapy-induced neuropathic pain

The broader US equity market provides the trading backdrop for Dogwood Therapeutics, with current S&P 500 market coverage available separately.

More news and analyses on Dogwood Therapeutics stock.

Disclaimer...
en | US92829J2033 | DWTX | boerse | 70533235 | bgmi